MedPath

Stichting European Myeloma Network

🇳🇱Netherlands
Ownership
Private
Employees
-
Market Cap
-
Website
https://esnaonline.wordpress.com/

Clinical Trials

42

Active:18
Completed:13

Trial Phases

3 Phases

Phase 1:18
Phase 2:13
Phase 3:8

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials

Phase 1
18 (46.2%)
Phase 2
13 (33.3%)
Phase 3
8 (20.5%)

European Myeloma Network (EMN) Sample Project

Recruiting
Conditions
Multiple Myeloma
Plasma Cell Leukemia
Extramedullary Myeloma
MGUS
Smoldering Multiple Myeloma
First Posted Date
2024-02-01
Last Posted Date
2025-04-15
Lead Sponsor
European Myeloma Network B.V.
Target Recruit Count
6000
Registration Number
NCT06237803
Locations
🇦🇹

KUK Linz, Linz, Austria

🇦🇹

Ordensklinikum Linz, Linz, Austria

🇦🇹

Medical University Vienna, Wien, Austria

and more 27 locations

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

Phase 2
Recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2024-01-05
Last Posted Date
2024-04-23
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
200
Registration Number
NCT06189833
Locations
🇦🇹

Innsbruck Medical University, Innsbruck, Austria

🇦🇹

Ordensklinikum Linz, Linz, Austria

🇦🇹

Clinic Ottakring, Vienna, Austria

and more 28 locations

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Phase 2
Recruiting
Conditions
Smoldering Multiple Myeloma
Interventions
First Posted Date
2023-12-27
Last Posted Date
2024-10-18
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
50
Registration Number
NCT06183489
Locations
🇫🇮

Helsinki University Hospital, Helsinki, Finland

🇫🇷

CHD Vendée, La Roche-sur-Yon, France

🇫🇷

CHRU de Lille - Hopital Claude Huriez, Lille, France

and more 22 locations

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

First Posted Date
2022-02-25
Last Posted Date
2025-05-28
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
750
Registration Number
NCT05257083
Locations
🇺🇸

University of Arkansas, Little Rock, Arkansas, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

UC San Diego Health Moores Cancer Center, San Diego, California, United States

and more 106 locations

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Phase 3
Recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2022-02-17
Last Posted Date
2025-07-08
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
1594
Registration Number
NCT05243797
Locations
🇺🇸

The University of Arizona Cancer Center, Phoenix, Arizona, United States

🇺🇸

University of California-Davis Cancer Center, Sacramento, California, United States

🇺🇸

University of California, San Diego (UCSD) Medical Center, San Diego, California, United States

and more 204 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath